Hu-Mik-Beta-1

Leukemia

National Cancer Institute (NCI)Phase 1Dormant

CC

40/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3	BB
THIOGUANINE ANHYDROUS Incyte Corporation	Phase 3	BB
Idarubicine Affiliated Hospital of Nantong University	Phase 3	BB
Daunorubicin Richard Stone, MD	Phase 3	BB

View all 50 →

Same molecule, other indications

Hu-Mik-Beta-1 is also rated in:

T-cell large granular lymphocyte leukemiaDormant

CC

Indicative ·

47 / 100

celiac diseaseDormant

CC

Indicative ·

46 / 100

Leukemia, T-Cell Large Granular LymphocyticDormant

NR

Indicative ·

/ 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.